ReviewJAC-antimicrobial resistance2025
Global prevalence of human intestinal carriage of ESBL-producing
Review in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence and antimicrobial resistance patterns of Escherichia coli isolates from humans and animals in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Hepatitis B surface antigen seroprevalence in Morocco (2000-2024): a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Global research trends, thematic evolution, and one health implications of ESBL-producing Escherichia coli: a bibliometric and science mapping analysis, 2001-2025.Folia microbiologica · 2026Article
- Implementation of wastewater-based epidemiology in a Northern California acute care hospital: a pilot study, June-July 2024.The Journal of hospital infection · 2026Article
- Risk factors associated with rectal carriage of extended spectrum beta-lactamases producing Enterobacterales among inpatients at a tertiary hospital in Northern Nigeria: A cross-sectional study.Scientific reports · 2026Article
- Comparison of the antimicrobial, anti-biofilm, and cytotoxic effects of thymol/ampicillin and thymol/cefotaxime against Escherichia coli bacteria.BMC research notes · 2026Article
- Seven-Year Surveillance and AI-Based Forecasting of Antimicrobial Resistance in PediatricInfection and drug resistance · 2026Article
- EprX associates with concurrent shifts in antimicrobial resistance and virulence in clinical bloodstreamFrontiers in cellular and infection microbiology · 2026Article
- Risk Factors Associated with Community-Onset Infections Due to Multidrug-Resistant Organisms.Antibiotics (Basel, Switzerland) · 2025Article
- Cefixime-clavulanic acid in ESBL-producing E. coli lower urinary tract infections: a 13-patient case series.BMC infectious diseases · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is a pressing need for global surveillance of ESBL-producing Methods: Four databases, including Embase, MEDLINE, PubMed and Web of Science, were searched for quantitative studies that reported prevalence data of faecal carriage of ESBL-producing Results: Of the 25 studies (13 901 unique participants) included for final analysis, the overall pooled prevalence of ESBL Conclusions: The pooled prevalence of ESBL
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.